Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026
Covered in this story
Analyst targets on Incyte
- H.C. Wainwright: $125 → $152 by Sep 2027 · Buy via Investing.com
- Oppenheimer: $130 → $120 by Jul 2027 · Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INCY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Incyte →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.